The aim of this study was to evaluate the prognostic significance of FGFR3 and EGFR expression in recurrent muscle-invasive bladder cancer (MIBC).

A total of 73 patients with histologically confirmed recurrent MIBC were included in the study. The expression levels of the markers were assessed using immunohistochemistry, and survival outcomes were evaluated using the Kaplan–Meier method and Cox proportional hazards model.

High EGFR expression was associated with poor tumor differentiation, early recurrence, and a statistically significant decrease in 3-year overall survival (p = 0.003). FGFR3 showed moderate prognostic significance. In multivariate analysis, EGFR emerged as an independent risk factor (HR = 2.17; p = 0.006).

The findings confirm the significance of EGFR as a prognostic biomarker in recurrent MIBC and highlight its potential as a target for personalized therapy.

Muscle-invasive bladder cancer, recurrence, prognostic markers

Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2021. CA Cancer J Clin. 2021;71(5):408–425. doi:10.3322/caac.21659

Siefker-Radtke AO, Necchi A, Park SH, et al. Molecular subtypes in muscle-invasive bladder cancer: time for change. Ann Oncol. 2020;31(8):968–980. doi:10.1016/j.annonc.2020.04.482

Kompier LC, Lurkin I, van der Aa MN, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010;5(11):e13821. doi:10.1371/journal.pone.0013821

Robinson BD, Vlachostergios PJ, Bhinder B, et al. Molecular characterization of recurrent muscle-invasive bladder cancer. Eur Urol Focus. 2020;6(3):514–523. doi:10.1016/j.euf.2019.01.012

Necchi A, Raggi D, Gallina A, et al. Update on emerging immunotherapies for urothelial carcinoma. Nat Rev Urol. 2022;19(2):101–115. doi:10.1038/s41585-021-00547-2

Choudhury A, Pantel K. EGFR pathway activation and resistance to cisplatin-based chemotherapy in urothelial carcinoma. Cancer Treat Rev. 2021;95:102153. doi:10.1016/j.ctrv.2021.102153

Guo G, Sun X, Chen C, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in chromatin remodeling genes. Nat Genet. 2013;45(12):1469–1475. doi:10.1038/ng.2798

Kim PH, Cha EK, Sfakianos JP, et al. Genomic predictors of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Clin Genitourin Cancer. 2015;13(2):e71–e77. doi:10.1016/j.clgc.2014.08.004

The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–322. doi:10.1038/nature12965

Al-Ahmadie HA, Iyer G, Hohl M, et al. Frequent somatic mutations of chromatin-remodeling genes in bladder cancer: clinical and biological implications. Nat Rev Urol. 2021;18(6):303–315. doi:10.1038/s41585-021-00450-w.